3SOF

Looking sweet indeed my fellow traders ....

Volume: 1,569,600
Avg Vol (3m): 684,313


Technicals
Most Actives
Percentage Gainer

Last Price Quote is:
12.29%above 13-day EMA
28.92%above 50-day EMA
RS Rating: 98 

YES that is awesome!!!!!!!! Great find much APPLAUSE!

Keepin my eye on this one, Likley buying on the break of the triangle.

Price action testing support currently, Hoping to see a bounce of this ascending trendline.

-fous

Quote from: fous on March 07, 2006, 10:48:58 PM
Keepin my eye on this one, Likley buying on the break of the triangle.

Price action testing support currently, Hoping to see a bounce of this ascending trendline.

-fous

I think she is headed that way Fous...
Stochastic is in a good buy area, way down in the oversold area, has turned north.
Stochastic presents a buy opportunity. JMHO of course.

Recent CandleStick Analysis
Very Bullish
Mar-09-2006 Bullish Engulfing

Today's Candlestick Patterns:
White Opening Marubozu
Today a White Opening Marubozu was formed. This shows that the day opened and then the prices continued to go up all day long without coming below the opening level thus forming a long white body, however prices did not close at the high of the day and thus they created an upper shadow.

Support @ $1.54...1.36...1.30
Resistance @ $1.66...1.70...1.87

Technicals
Close Above the 13-day EMA
Percentage Gainer

Last Price Quote is:
3.00%above 13-day EMA
15.80%above 50-day EMA
RS Rating: 97 

Candle patterns looking nice as well as  bouncing off support. I see a nice risk/reward here. Buying at the open. For now i'll continue to hold as long as price action closes above the ascending triangle.

-fous

Press Release Source: InSite Vision Incorporated


InSite Vision to Hold Conference Call to Discuss Top Line Results of Second Phase 3 Clinical Trial on Tuesday, March 14th
Monday March 13, 7:00 am ET


ALAMEDA, Calif.--(BUSINESS WIRE)--March 13, 2006--InSite Vision Incorporated (AMEX:ISV - News) an ophthalmic therapeutics, diagnostics and drug-delivery company announced today that the Company will hold a conference call to discuss the top line results from the second of two required phase 3 clinical trials of AzaSite (azithromycin 1% solution in DuraSite®) on Tuesday, March 14, 2006.


S. Kumar Chandrasekaran, Ph.D., Chief Executive Officer, will host a conference call beginning at 4:30 p.m. Eastern Time on Tuesday, March 14, 2006 to discuss the top line results of the clinical trial and to answer questions.

Individuals interested in listening to the conference call may do so by dialing toll free (877) 407-0778 or (201) 689-8565. A telephone replay will be available for 48 hours following the conclusion of the call by dialing toll-free (877) 660-6853 or (201) 612-7415. All callers will have to enter the Play back account number 286 and Conference ID number: 195622.

The live conference call is being webcast by Vcall and can also be accessed via the investor relations section of the Company's website at www.insite.com or through www.InvestorCalendar.com. A recording of the call will be available for 90 days following the completion of the call.

About InSite Vision

InSite Vision is an ophthalmic company focused on developing therapies that treat ocular infections, glaucoma and retinal diseases. InSite Vision's lead product is AzaSite, which targets infections of the eye. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSite, InSite Vision's patented drug-delivery vehicle, which offers the benefit of a low-dosing regimen, attractive to both the eye-care patient and physician. Pending the successful results of phase 3 clinical testing currently underway and filing and approval of an NDA with the FDA, the Company currently expects AzaSite to be commercially launched in the United States, while seeking to expand this "technology platform" to include additional product candidates and indications for the worldwide market.

In the glaucoma area, the Company continues to focus genomic research on the TIGR gene, among other genes in its genomic portfolio. A portion of this research has been incorporated into the Company's commercially available OcuGene® glaucoma genetic test for disease management, which is a prognostic tool designed to detect a genetic marker (mt-1) in the promoter region of the glaucoma-related TIGR gene.

Additional information can be found at the Company's website, www.insitevision.com.

This news release contains, among other things, certain statements of a forward-looking nature relating to future events or the future business performance of InSite Vision, such as the timing of initiation and completion of current and future clinical trials, the success thereof, the timing of filing an NDA with the FDA, expected marketing plan for AzaSite, the potential benefits and commercialization of AzaSite, and the timing and success thereof, the expected date and forum for presenting AzaSite research results and the Company's plans to pursue expanding the AzaSite "technology platform." Such statements entail a number of risks and uncertainties, including but not limited to: InSite Vision's ability to obtain additional financing, InSite Vision's ability to enroll and complete future clinical trials for AzaSite; the results of InSite Vision's AzaSite clinical trials; InSite Vision's ability to commence, complete and file an NDA with the U.S. FDA for AzaSite and its other product candidates, and receive approval from the FDA for the commercialization of AzaSite and its other product candidates; InSite Vision's ability to launch AzaSite and the timing of such a launch; InSite Vision's ability to expand its technology platform to include additional indications and patent options; the effects of its expense control activities on its operations and product development; InSite Vision's ability to maintain and develop additional collaborations and commercial agreements with corporate partners, including those with respect to AzaSite and ISV-205; its reliance on third parties for the development, marketing and sale of its products; the initiation and results of preclinical and clinical studies; its ability to adequately protect its intellectual property and to be free to operate with regard to the intellectual property of others, determinations by the FDA, including those with respect to OcuGene, AzaSite and ISV-205 and InSite's ability to present such results at an upcoming international conference. Reference is made to the discussion of risk factors detailed in InSite Vision's filings with the Securities and Exchange Commission, including its annual report on Form 10-K, as amended, and its quarterly reports on Form 10-Q. All forward looking statements in this press release and/or conference call are based on the limited information currently available to InSite Vision, which is subject to change. Although any such projections and the factors influencing them will likely change, InSite Vision undertakes no obligation to update the information. Such information speaks only as of the date of its release. Actual events or results could differ materially and one should not assume that the information provided in this release and/or conference call is still valid at any later date.

Note to Editors: OcuGene® is written with a "small cap" G; if doing so is not possible, please use an upper case G. InSite Vision Incorporated, InSite Vision, DuraSite® and OcuGene® are trademarks of InSite Vision Incorporated.

Contact:
InSite Vision Incorporated
S. Kumar Chandrasekaran or Sandra Heine, 510-865-8800
www.insitevision.com

--------------------------------------------------------------------------------
Source: InSite Vision Incorporated

Nice movement again for this one today.  "Let's Rock Fous!"
Volume: 1,097,200
Avg Vol (3m): 663,295

Technicals
Record Price High
Close Above the 13-day EMA
Most Actives
Record Price Break Out
Percentage Gainer

Last Price Quote is:
12.19%above 13-day EMA
26.13%above 50-day EMA
RS Rating: 98 

InSite reports positive late-stage results for eye drops...
InSite Vision Announces Second of Two Phase 3 Clinical...
This is a strong trend.

Technicals
Most Actives
Percentage Gainer

Last Price Quote is:
18.82%above 13-day EMA
36.20%above 50-day EMA
RS Rating: 98 

Press Release Source: InSite Vision Incorporated


InSite Vision Announces Second of Two Phase 3 Clinical Trials Results Meet Primary and Secondary Efficacy End Points
Tuesday March 14, 7:00 am ET 
Preparations for AzaSite(TM) New Drug Application


ALAMEDA, Calif.--(BUSINESS WIRE)--March 14, 2006--InSite Vision Incorporated (AMEX:ISV - News) today announced top-line results from the second of two required phase 3 clinical trials to evaluate the safety and efficacy of AzaSite(TM) (1.0% azithromycin solution in DuraSite®) anti-infective eye drops in patients with bacterial conjunctivitis. In a study to show superiority of AzaSite relative to vehicle, patients treated with AzaSite had a significantly higher clinical resolution rate, the trial's primary efficacy end point and a significantly higher bacterial eradication rate, a secondary end point, than those receiving placebo. Importantly, the study also showed that AzaSite was safe and well tolerated. The data from which these top-line clinical results were drawn, will be reported at an upcoming ophthalmology conference.


S. Kumar Chandrasekaran, Ph.D., InSite Vision's CEO stated, "The completion of these two phase 3 clinical trials is a significant milestone for our company. The data demonstrates the success of our strategy to use the DuraSite platform to develop anti-infective therapies with reduced dosing frequency. The clinical resolution rate of less frequently dosed AzaSite is comparable to the best selling ophthalmic antibiotic products. The reduced dosing frequency can lead to improved compliance, greater patient convenience and better therapeutic outcomes. We look forward to presenting our data for scientific review and to the submission of our AzaSite NDA to the Food and Drug Administration this year."

Trial Design and Results

This second of two phase 3 trials was an international, double-blind, randomized, vehicle-controlled study that was conducted at 42 centers in the United States and 11 in Mexico and Central America. The trial enrolled 685 subjects of which 240 ranged in age from 1 to 16 years. Those subjects with confirmed bacterial conjunctivitis (pink-eye), a common infectious ocular disease, were evaluated for efficacy, whereas all subjects enrolled in the trial were evaluated for safety. Trial participants received eye drops of either placebo or AzaSite for 5 days. The drops were dosed twice a day for the first 2 days, followed by once a day for the next 3 days. Demographic characteristics were evenly distributed across treatment groups.

The Phase 3 trial was designed to compare the resolution of clinical signs and symptoms of bacterial conjunctivitis in subjects that had been treated with AzaSite versus those that had been treated with placebo. Top-line results showed that the clinical resolution rate, the trial's primary efficacy end point, was significantly higher in subjects treated with AzaSite than those treated with placebo (p less than 0.03). Furthermore, the bacterial eradication rate, the trial's secondary efficacy end point, was also significantly higher in the AzaSite treated group (p less than 0.001).

Preliminary safety data from the second phase 3 study showed that AzaSite was well tolerated in adult and pediatric subjects. There were no reports of systemic drug sensitivity due to study medication. No serious adverse events that were related to the study medications were reported by the clinical sites. Ocular adverse events were minimal in frequency and equivalent between the two groups. The statistical analysis of the entire dataset is still ongoing. The final results will be presented at an upcoming international ophthalmology conference.

About Bacterial Conjunctivitis

Bacterial conjunctivitis is a common ocular surface disease characterized by inflammation of the delicate skin and mucosa on the inside of the eyelids. The bacterial infections are contagious and generally accompanied by irritation, itching, foreign body sensation, watering, mucus discharge and redness (pink-eye). The bacterial form of the disease is more common in children than adults. In children, the most common bacterial species associated with acute conjunctivitis are Hemophilus influenzae, Streptococcus pnuemoniae, and Staphylococcus species. Among adults, bacterial conjunctivitis can be an important concern in contact lens wearers. The disease is self-limiting in most cases and usually resolves in 8-10 days. Topical antibiotics are often prescribed to control the public health risk of contagion and to shorten the duration of the disease.

Conference Call

S. Kumar Chandrasekaran, Ph.D., Chief Executive Officer will host a conference call beginning at 4:30 a.m. Eastern Time to discuss these top-line clinical results and answer questions along with Dr. Warren H. Heller, a principal investigator in the clinical trial and ophthalmologist in private practice in Phoenix, Arizona.

Individuals interested in listening to the conference call may do so by dialing toll free (877) 407-0778 or (201) 689-8565. A telephone replay will be available for 48 hours following the conclusion of the call by dialing (877) 660-6853 or (201) 612-7415. Callers will have to enter the Play Back account number 286 and Conference ID number: 195622.

The live conference call is being webcast by Vcall and can also be accessed via the investor relations section of the Company's website at www.insite.com or through www.InvestorCalendar.com. A recording of the call will be available for 90 days following the completion of the call.

About InSite Vision Incorporated

InSite Vision is an ophthalmic company focused on developing therapies that treat ocular infections, glaucoma and retinal diseases. InSite Vision's lead product is AzaSite, which targets infections of the eye. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSite, InSite Vision's patented drug-delivery vehicle, which offers the benefit of a low-dosing regimen, attractive to both the eye-care patient and physician. Pending the successful results of phase 3 clinical testing currently underway and filing and approval of an NDA with the FDA, the Company currently expects AzaSite to be commercially launched in the United States, while seeking to expand this "technology platform" to include additional product candidates and indications for the worldwide market.

In the glaucoma area, the Company continues to focus genomic research on the TIGR gene, among other genes in its genomic portfolio. A portion of this research has been incorporated into the Company's commercially available OcuGene® glaucoma genetic test for disease management, which is a prognostic tool designed to detect a genetic marker (mt-1) in the promoter region of the glaucoma-related TIGR gene.

Additional information can be found at the Company's website, www.insitevision.com.

This news release contains, among other things, certain statements of a forward-looking nature relating to future events or the future business performance of InSite Vision, such as the timing of initiation and completion of current and future clinical trials, the success thereof, the timing of filing an NDA with the FDA, expected marketing plan for AzaSite, the potential benefits and commercialization of AzaSite, and the timing and success thereof, the expected date and forum for presenting AzaSite research results and the Company's plans to pursue expanding the AzaSite "technology platform." Such statements entail a number of risks and uncertainties, including but not limited to: InSite Vision's ability to obtain additional financing, InSite Vision's ability to enroll and complete future clinical trials for AzaSite; the results of InSite Vision's AzaSite clinical trials; InSite Vision's ability to commence, complete and file an NDA with the U.S. FDA for AzaSite and its other product candidates, and receive approval from the FDA for the commercialization of AzaSite and its other product candidates; InSite Vision's ability to launch AzaSite and the timing of such a launch; InSite Vision's ability to expand its technology platform to include additional indications and patent options; the effects of its expense control activities on its operations and product development; InSite Vision's ability to maintain and develop additional collaborations and commercial agreements with corporate partners, including those with respect to AzaSite and ISV-205; its reliance on third parties for the development, marketing and sale of its products; the initiation and results of preclinical and clinical studies; its ability to adequately protect its intellectual property and to be free to operate with regard to the intellectual property of others, determinations by the FDA, including those with respect to OcuGene, AzaSite and ISV-205 and InSite's ability to present such results at an upcoming international conference. Reference is made to the discussion of risk factors detailed in InSite Vision's filings with the Securities and Exchange Commission, including its annual report on Form 10-K, as amended, and its quarterly reports on Form 10-Q. All forward looking statements in this press release and/or conference call are based on the limited information currently available to InSite Vision, which is subject to change. Although any such projections and the factors influencing them will likely change, InSite Vision undertakes no obligation to update the information. Such information speaks only as of the date of its release. Actual events or results could differ materially and one should not assume that the information provided in this release and/or conference call is still valid at any later date.

Note to Editors: OcuGene® is written with a "small cap" G; if doing so is not possible, please use an upper case G. InSite Vision Incorporated, InSite Vision, DuraSite® and OcuGene® are trademarks of InSite Vision Incorporated. Other trademarks that may be mentioned in this release are the intellectual property of their respective owners.

Contact:
InSite Vision Incorporated
S. Kumar Chandrasekaran or Sandra Heine, 510-865-8800
www.insitevision.com

--------------------------------------------------------------------------------
Source: InSite Vision Incorporated

InSite reports positive late-stage results for eye drops
Tue Mar 14, 2006 7:27 AM ET
March 14 (Reuters) - InSite Vision Inc. (ISV.A: Quote, Profile, Research) on Tuesday reported positive results from the second of two late-stage clinical trials to test its anti-infective eye drop AzaSite in patients with bacterial conjunctivitis.

The opthalmic company said in a statement it plans to submit a new drug application form to the U.S. Food and Drug Administration for AzaSite this year. (Reporting by Nupur Sen in Bangalore)

Rocking and a rolling....


Technicals
Record Price High........
Most Actives
Percentage Gainer

Last Price Quote is:
23.05%above 13-day EMA
42.82%above 50-day EMA
RS Rating: 99 

im lovin this peg leg 

-fous

 

Technicals
Last Price Quote is:
15.48%above 13-day EMA
37.61%above 50-day EMA
RS Rating: 98 

Fundamentals
Key Data:
Market Cap (M): $30.56 

Has been a Strong Move,Lets see if the momentum carries us.
I was ready for a dip but I am definitely holding on for a bigger ride.

Volume: 1,108,500
Avg Vol (3m): 793,877

Technicals
Record Price High
Percentage Gainer

Last Price Quote is:
17.50%above 13-day EMA
41.04%above 50-day EMA
RS Rating: 99 

With this chart it is a stock worth holding onto with only a trailing stop.
This stock is poised for much higher prices over the coming months after a
consolidation period here.Stochastic bouncing up out of oversold area,buy zone.

Going in and out of stocks is not a strategy that will generate the great profits you really want. Finding a winner and sticking with it until it hits a trailing stop is the way to Real earnings.